[{"orgOrder":0,"company":"Polysan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Polysan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Inapplicable"},{"orgOrder":0,"company":"Polysan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Neurology","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Polysan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Inapplicable"},{"orgOrder":0,"company":"Polysan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Polysan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Inapplicable"},{"orgOrder":0,"company":"Superficial Siderosis Research Alliance Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Hematology","graph2":"Undisclosed","graph3":"Superficial Siderosis Research Alliance Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Superficial Siderosis Research Alliance Inc. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Superficial Siderosis Research Alliance Inc. \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Selfer

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 07, 2023

                          Lead Product(s) : Inosine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Superficial Siderosis Research Alliance Inc.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Superficial Siderosis Research Alliance Inc.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          May 18, 2021

                          Lead Product(s) : Inosine

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          December 02, 2020

                          Lead Product(s) : Inosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          November 17, 2020

                          Lead Product(s) : Inosine

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 21, 2019

                          Lead Product(s) : Inosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Bellerophon Pulse Technologies

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Bellerophon Pulse Technologies

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2018

                          Lead Product(s) : Inosine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Worldwide Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Runihol

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          October 12, 2016

                          Lead Product(s) : Inosine

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Michael Alan Schwarzschild

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Michael Alan Schwarzschild

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Inosine

                          Therapeutic Area : Neurology

                          Study Phase : Phase III

                          Sponsor : Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          December 30, 2015

                          Lead Product(s) : Inosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank